 |
Previous Article | Next Article 
The Journal of Neuroscience, 1999:RC10:1-5
RAPID COMMUNICATION
Histochemically Reactive Zinc in Plaques of the Swedish Mutant
-Amyloid Precursor Protein Transgenic Mice
Joo-Yong
Lee,
Inhee
Mook-Jung, and
Jae-Young
Koh
National Creative Research Initiative Center for the Study of CNS
Zinc and Department of Neurology, University of Ulsan College of
Medicine, Seoul 138-736, Korea
 |
ABSTRACT |
Endogenous metals such as zinc may contribute to -amyloid (A )
aggregation and hence the plaque formation. In the present study, we
examined brains of four Swedish mutant amyloid precursor protein (APP)
transgenic mice at 12 months of age for histochemically reactive zinc
in the plaques. Here, we report that all the Congo red (+)
mature plaques contained chelatable zinc, as demonstrated by
staining with the zinc-specific fluorescent dye
6-methoxy-8-quinolyl-para-toluenesulfonamide (TSQ). On the other hand, Congo red ( ) preamyloid A deposits were
not stained with TSQ. Interestingly, although cerebellum contained
similar degree of preamyloid A deposits as cerebral cortex, it was
completely devoid of Congo red- or TSQ-stained mature plaques. Although
zinc from plaques was only slowly and partially removed by a specific
zinc remover, dithizone, treatment of brain sections with
heparinase-III, which degrades heparan sulfate proteoglycan (HSPG),
another major constituent of plaques, greatly fastened the zinc removal
with dithizone.
The present study has demonstrated the presence of histochemically
reactive zinc in plaques, but not preamyloid A deposits, of the
Swedish mutant APP transgenic mice. Because preamyloid A deposits
fail to develop into congophilic plaques in cerebellum where synaptic
vesicle zinc is deficient, the synaptic zinc may be a necessary element
in the plaque formation. In holding zinc inside plaques, HSPG may
contribute in addition to A .
Key words:
-amyloid; Alzheimer's disease; heparan sulfate
proteoglycan; metal; cortex; cerebellum
 |
INTRODUCTION |
One of the hallmark pathological
features of Alzheimer's disease (AD) is the accumulation of amyloid
plaques in the brain. The main component of the amyloid plaque is the
peptide fragment of 39-43 amino acid residues (A ), derived from
-amyloid precursor protein (APP) of 695-771 amino acids (Kang et
al., 1987 ). Recent studies suggest that abnormal processing of APP and
accumulation of amyloid plaques may play a causal role in the
pathogenesis of AD. First, all the identified mutant genes causing
familial AD (APP and presenilin-1 and -2) have been shown to increase
A production (Price and Sisodia, 1998 ). Second, transgenic mice overexpressing human mutant APP develop not only the accumulation of
amyloid plaques but also deficits in learning (Games et al., 1995 ;
Hsiao et al., 1996 ). Finally, aggregated A induces neuronal death in
cultures (Pike et al., 1993 ).
In light of evidence that A accumulation and plaque formation play a
pivotal role in the AD pathogenesis, understanding the precise
mechanisms of the process may be crucial for contemplating effective
treatments against AD. Recently, Bush et al. (1994a) and Atwood
et al. (1998) showed that zinc and copper promote A aggregation in test tube conditions and suggested that these endogenous metals may contribute to the process of the plaque formation. Corroborating this hypothesis, they showed that metal chelators increase extraction of A from the human AD brains (Cherny et al.,
1998 ). Furthermore, examination of AD brains revealed that chelatable
zinc is present in plaques and tangles (Suh et al., 1998 ). Although
these data support the metal, in particular zinc, hypothesis in plaque
formation, it is difficult to test this directly in human patients.
Cell membrane-permeant metal chelators such as
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine
are highly toxic to neurons (Ahn et al., 1998 ). On the other hand,
nontoxic extracellular metal chelators such as Ca-EDTA do not cross the blood-brain barrier and hence should be applied into parenchyme or
CSF. Because this requires invasive procedures, careful animal experiments are warranted before testing it in human patients. For this
reason, we examined whether zinc is identifiable in plaques of
transgenic mice overexpressing the Swedish mutant APP (Hsiao et al.,
1996 ).
 |
MATERIALS AND METHODS |
Transgenic mice. Transgenic mice overexpressing
Swedish mutant APP (Tg2576) (Hsiao et al., 1996 ) were generous gift
from Dr. K. Hsiao (University of Minnesota, Minneapolis, MN). For the
present study, four female Tg2576 mice at 12 months of age were used. According to the report of Hsiao et al. (1996) , -amyloid plaques begin to appear at 9 months after birth in the Tg2576 mouse brain.
Tissue preparation and Congo red staining. Brains of Tg2576
mice were harvested and immediately frozen in dry ice. Coronal brain
sections of 10 µm thickness were obtained using a cryostat (Leica,
Nussloch, Germany) and mounted on glass slides. Plaques were identified
by staining brain sections with Congo red. After staining in Mayer's
hematoxylin solution for 10 min, brain sections were rinsed in tap
water for 5 min and incubated in alkaline sodium chloride solution for
20 min. Brain sections were then stained with alkaline Congo red
solution (0.2% in 80% ethanol saturated with sodium chloride; Sigma,
St. Louis, MO) and washed in absolute ethanol. Congo red-stained
sections were observed under light microscope (conventional and polarized).
Immunocytochemistry. A deposits inside and outside
congophilic plaques were visualized immunocytochemically with mouse
monoclonal antibody 4G8 (Senetek, St. Louis, MO) specific for
A 17-24. Immunocytochemistry was performed using the
avidin-biotin-horseradish peroxidase method (Vector Laboratories,
Burlingame, CA). Briefly, frozen brain sections were blocked with horse
serum and immunoreacted overnight with 4G8 at 1:1000 dilution. After
reaction with biotinylated secondary antibody (horse anti-mouse IgG),
sections were treated with avidin-horseradish peroxidase solution.
After thorough rinsing with PBS, sections were incubated in solution
containing 0.015% diaminobenzidine and 0.001% hydrogen peroxide.
To immunocytochemically verify the degradation of heparan sulfate
proteoglycan (HSPG) in plaques after treatment with heparinase-III, anti- -heparan sulfate antibody 3G10 (Seikagaku, Tokyo, Japan) specific for heparinase-digested heparan sulfate side chains was used
(1:50).
Fluorescent zinc staining. To examine the presence of
chelatable zinc in plaques, brain sections were stained with
6-methoxy-8-quinolyl-para-toluenesulfonamide (TSQ)
(Frederickson et al., 1987 ). Without fixation, frozen sections were
immersed for 90 sec in TSQ solution (4.5 µM; Molecular
Probes, Eugene, OR) in 140 mM sodium barbital and 140 mM sodium acetate buffer, pH 10. After washing with normal
saline, TSQ fluorescence was examined under a fluorescence microscope
with an ultraviolet filter (excitation, 355-375 nm;
dichroic, 380 nm; barrier, 420 nm).
Removal of tissue zinc with dithizone. Dithizone
specifically removes zinc from tissue (Koh et al., 1996 ). Brain
sections were immersed in 10 mM dithizone for 5 min at room
temperature. After rinsing with normal saline, brain sections were
examined for TSQ fluorescence.
Heparinase-III treatment. To digest HSPG in brain sections,
frozen brain sections were incubated at 37°C for 2 hr in
heparinase-III-containing PBS (2 U in 200 µl; Sigma). The
enzyme reaction was terminated by rinsing brain sections multiple times
with normal saline.
 |
RESULTS |
Brains of four Swedish mutant APP transgenic mice were examined at
12 months of age, when they developed numerous congophilic plaques with
apple green birefringence in cerebral cortex and hippocampus, as
previously reported (Hsiao et al., 1996 ) (Fig. 1A,B). On the other
hand, immunocytochemical staining of an adjacent section with
anti-A 17-24 antibody recognized not only congophilic plaques but
also more widespread preamyloid A deposits (Fig. 1C). TSQ
staining revealed that all the congophilic plaques contained chelatable
zinc (Fig. 1D). However, preamyloid A deposits
were not stained for zinc with TSQ. Changing the order of staining, first TSQ and then Congo red, did not alter the correlation, ruling out
the possibility that zinc fluorescence is merely an artifact of Congo
red staining.

View larger version (159K):
[in this window]
[in a new window]
|
Figure 1.
A, Cerebral cortex of an APP
transgenic mouse at 12 months of age was stained with Congo red. Note
numerous congophilic plaques. B, Hippocampus of another
APP transgenic mouse with Congo red staining without
(top) or with (bottom) polarization. Note
that all Congo red (+) plaques exhibit apple green birefringence
(arrows). C, Anti-A antibody
(monoclonal antibody 4G8)-stained plaques (arrowheads;
subsequently identified with Congo red staining) and preamyloid A
deposits (arrows) in cortex. D, Cortices
were stained with Congo red (top) and subsequently with
a specific zinc fluorescent dye, TSQ (bottom). Note that
all congophilic plaques were subsequently stained with TSQ. Changing
the order of staining, first TSQ and then Congo red, produced identical
results. Scale bars, 500 µm.
|
|
In contrast to forebrain, cerebellum lacks synaptic zinc (Frederickson,
1989 ; Fig. 2B).
Consistent with the hypothesis that synaptic zinc may contribute to
plaque formation, cerebellum contained neither Congo red-stained (Fig.
2A) nor TSQ-stained (Fig. 2B) plaques. However, cerebellum still exhibited a substantial amount of
preamyloid A deposits (Fig. 2C), as did cortex and
hippocampus.

View larger version (73K):
[in this window]
[in a new window]
|
Figure 2.
A, Congo red staining of cerebellum
revealed no congophilic plaque. B, No TSQ-stainable
structure, plaque or presynaptic zinc, was found in cerebellum.
C, Anti-A antibody revealed similar amounts of
preamyloid A deposits (arrows) in cerebellum as in
cerebral cortex (Fig. 1C). Scale bars, 500 µm.
|
|
Interestingly, treatment of plaques with a specific zinc remover,
dithizone (10 mM) (Koh et al., 1996 ), for 5 min, which
abolished background zinc fluorescence presumably in presynaptic
vesicles, did not much reduce the fluorescence in plaques (Fig.
3B). This suggested that some
of the zinc in plaques was not easily accessible for dithizone. Because
HSPG, another major constituent of plaques, may contribute to A
aggregation (Snow et al., 1988 ; Brunden et al., 1993 ), we examined
whether it is involved in holding zinc. The treatment of adjacent brain
sections of the above with heparinase-III for 2 hr degraded HSPG
in plaques, as evidenced by the emergence of immunoreactivity to an
antibody (3G10) specific for digested heparan sulfate side chains (Fig.
3E). The heparinase-III treatment rendered zinc removal by dithizone
much faster. Subsequent to the heparinase-III treatment, 5 min exposure
to dithizone completely abolished TSQ fluorescence in the plaques (Fig.
3C, compare with B). In contrast, even 30 min exposure to 10 mM dithizone in naïve tissue
only partially removed zinc in plaques (Fig. 3D). This finding suggests that HSPG indeed contributes to holding zinc in
plaques. However, despite complete removal of zinc, plaques were still
stained with anti-A antibody (Fig. 3F) or Congo
red (Fig. 3G).

View larger version (86K):
[in this window]
[in a new window]
|
Figure 3.
A-D, Cerebral cortex stained with
TSQ before (A) and after 5 min treatment with 10 mM dithizone (B). Five minutes of
dithizone treatment abolished background zinc staining but only a
fraction of zinc staining in plaques. After 2 hr of treatment of an
adjacent section with heparinase-III, however, the same dithizone
treatment (5 min, 10 mM) completely removed all the zinc
(C). In contrast, even 30 min of treatment with
10 mM dithizone did not completely remove the TSQ
fluorescence in the plaque (D). E,
After treatment for 2 hr with heparinase-III, the antibody specific for
digested heparan sulfate side chains (3G10) stained plaques, indicating
that HSPG was degraded with the enzyme treatment. TSQ staining was not
altered by heparinase treatment alone. F, A brain
section was stained with anti-A antibody after complete removal of
zinc (heparinase-III and dithizone treatments). Although zinc was
completely removed (C), the immunoreactivity of plaques
to 4G8 did not change. G, Plaques retained stainability
to Congo red after the complete removal of zinc. Scale bars, 500 µm.
|
|
 |
DISCUSSION |
Our findings have demonstrated that TSQ-stainable zinc is
invariably present in mature congophilic amyloid plaques but not in
preamyloid A deposits of the Swedish mutant APP transgenic mice.
Combined with a report showing that human AD brains also contain
chelatable zinc in plaques (Suh et al., 1998 ), the present results
suggest that the presence of chelatable zinc may be a universal feature
of mature congophilic plaques. Because TSQ and dithizone are specific
for zinc, the fluorescent signal in plaques has likely originated from
zinc. With the histochemical methods used in the present study,
however, we cannot rule out a possible additional contribution of
copper in the plaque formation (Atwood et al., 1998 ). In addition,
because TSQ is a dye with relatively low affinity for zinc
(Frederickson et al., 1987 ), it remains a possibility that low-level or
tightly bound zinc is present even in preamyloid A deposits. In any
case, the fact that a large amount of chelatable zinc is invariably
present in mature congophilic plaques supports the hypothesis that
endogenous zinc contributes to the maturation of A plaques (Bush et
al., 1994a ). It has been shown that zinc binds to A with high and
low affinities, indicating the presence of specific binding sites (Bush
et al., 1994b ).
Interestingly, cerebellum lacking synaptic vesicle zinc (Frederickson,
1989 ), but containing similar amounts of tissue copper (Sato et al.,
1994 ), does not develop plaques in transgenic mice (present study) as
well as in human AD brains (Joachim et al., 1989 ), even if cerebellum
has substantial preamyloid A deposits. Although these findings argue
that zinc accumulation is unlikely only a result of its nonspecific
binding to a preformed -pleated sheet, the present study cannot
completely rule out this possibility. However, zinc preferentially
binds to soluble A ( -helical form) (Huang et al., 1997 ).
Furthermore, metal binding may promote conformational changes of A
to -pleated sheet (Vyas and Duffy, 1995 ). These data favor the idea
that the zinc binding may be a trigger for the conformation change of
A .
Further supporting the involvement of synaptic zinc rather than the
ambient submicromolar zinc or copper in extracellular fluid (Bush et
al., 1994a ) in the maturation of A plaques is the evidence
that 100 µM concentrations of zinc are needed to promote
A aggregation (Esler et al., 1996 ). At the peak of neuronal activity, such high concentrations of zinc can be attained by the
release of synaptic zinc (Assaf and Chung, 1984 ).
In addition to A , our findings suggest that HSPG may be also
involved in the zinc binding. Heparin and HSPG contain metal-binding domains (Whitfield and Sarkar, 1992 ). A recent study showed that the
presence of zinc could increase in the APP affinity for heparin (Multhaup et al., 1995 ). Hence, zinc may play a role in linking A
and HSPG to form dense congophilic plaques in AD.
The APP transgenic mice seem to be an ideal model to directly test the
hypothesis that endogenous synaptic zinc is necessary for the plaque
formation. For example, determining effects of metal chelators
administered into the brain or CSF during the time window of the plaque
formation in these mice ( 9 months of age) may be revealing.
Additionally, application of zinc into cerebellum of the Swedish APP
transgenic mice, where preamyloid A deposits are abundant but
plaques are lacking, may provide a parallel clue to this theory.
 |
FOOTNOTES |
Received Nov. 2, 1998; revised March 8, 1999; accepted March 18, 1999.
This study was supported by Creative Research Initiatives of the Korean
Ministry of Science and Technology (J.-Y.K.). We thank Dr. Karen Hsiao
for generously donating the APP transgenic mice.
Correspondence should be addressed to Jae-Young Koh, National Creative
Research Center for the Study of CNS Zinc, Department of Neurology,
University of Ulsan College of Medicine, 388-1 Poongnap-Dong Songpa-Gu,
Seoul 138-736, Korea.
 |
REFERENCES |
-
Ahn YH,
Kim YH,
Hong SH,
Koh JY
(1998)
Depletion of intracellular zinc induces protein synthesis-dependent neuronal apoptosis in mouse cortical culture.
Exp Neurol
154:47-56.
-
Assaf SY,
Chung SH
(1984)
Release of endogenous Zn2+ from brain tissue during activity.
Nature
308:734-736.
-
Atwood CS,
Moir RD,
Huang X,
Scarpa RC,
Bacarra NM,
Romano DM,
Hartshorn MA,
Tanzi RE,
Bush AI
(1998)
Dramatic aggregation of Alzheimer A
by Cu(II) is induced by conditions representing physiological acidosis.
J Biol Chem
273:12817-12826. -
Brunden KR,
Richter-Cook NJ,
Chaturvedi N,
Frederickson RC
(1993)
pH-dependent binding of synthetic beta-amyloid peptides to glycosaminoglycans.
J Neurochem
61:2147-2154.
-
Bush AI,
Pettingell WH,
Multhaup G,
de Paradis M,
Vonsattel JP,
Gusella JF,
Beyreuther K,
Masters CL,
Tanzi RE
(1994a)
Rapid induction of Alzheimer A beta amyloid formation by zinc.
Science
265:1464-1467.
-
Bush AI,
Pettingell WH,
Paradis MD,
Tanzi RE
(1994b)
Modulation of A beta adhesiveness and secretase site cleavage by zinc.
J Biol Chem
269:12152-12158.
-
Cherny RA, Legg JT, Beyreuther K, Tanzi RE, Masters CL, Bush
AI (1998) Differential effects of chelators upon the
solubilization of cerebral A
deposits in post-mortem Alzheimer and
control brain tissue. The 6th International Conference on Alzheimer's
Disease and Related Disorders, Amsterdam, The Netherlands. Neurobiol
Aging 19[Suppl 4S]:470. -
Esler WP,
Stimson ER,
Jennings JM,
Ghilardi JR,
Mantyh PW,
Maggio JE
(1996)
Zinc-induced aggregation of human and rat beta-amyloid peptides in vitro.
J Neurochem
66:723-732.
-
Frederickson CJ
(1989)
Neurobiology of zinc and zinc-containing neurons.
Int Rev Neurobiol
31:145-238.
-
Frederickson CJ,
Kasarskis EJ,
Ringo D,
Frederickson RE
(1987)
A quinoline fluorescence method for visualizing and assaying the histochemically reactive zinc (bouton zinc) in the brain.
J Neurosci Methods
20:91-103.
-
Games D,
Adams D,
Alessandrini R,
Barbour R,
Berthelette P,
Blackwell C,
Carr T,
Clemens J,
Donaldson T,
Gillespie F,
Guid T,
Hagopian S,
Johnson-Wood K,
Lee M,
Leibowitz P,
Lieberburg I,
Montoya-Zavala M,
Mucke L,
Power M,
Schenk D,
Seubert P,
Snyder B,
Soriano F,
Tan H,
Vitale J,
Wadsworth S,
Wolozin B,
Zhao J
(1995)
Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein.
Nature
373:523-527.
-
Hsiao K,
Chapman P,
Nilsen S,
Eckman C,
Harigaya Y,
Younkin S,
Yang F,
Cole G
(1996)
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.
Science
274:99-102.
-
Huang X,
Atwood CS,
Moir RD,
Hartshorn MA,
Vonsattel JP,
Tanzi RE,
Bush AI
(1997)
Zinc-induced Alzheimer's Abeta1-42 aggregation is mediated by conformational factors.
J Biol Chem
272:26464-26470.
-
Joachim CL,
Morris JH,
Selkoe DJ
(1989)
Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease.
Am J Pathol
135:309-319.
-
Kang J,
Lemaire HG,
Unterbeck A,
Salbaum JM,
Masters CL,
Grzeschik KH,
Multhaup G,
Beyreuther K,
Muller-Hill B
(1987)
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor.
Nature
325:733-736.
-
Koh JY,
Suh SW,
Gwag BJ,
He YY,
Hsu CY,
Choi DW
(1996)
The role of zinc in selective neuronal death after transient global cerebral ischemia.
Science
272:1013-1016.
-
Multhaup G,
Mechler H,
Masters CL
(1995)
Characterization of the high affinity heparin binding site of the Alzheimer's disease beta A4 amyloid precursor protein (APP) and its enhancement by zinc(II).
J Mol Recognit
8:247-257.
-
Pike CJ,
Burdick D,
Walencewicz AJ,
Glabe CG,
Cotman CW
(1993)
Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state.
J Neurosci
13:1676-1687.
-
Price DL,
Sisodia SS
(1998)
Mutant genes in familial Alzheimer's disease and transgenic models.
Annu Rev Neurosci
21:479-505.
-
Sato M,
Ohtomo K,
Daimon T,
Sugiyama T,
Iijima K
(1994)
Localization of copper to afferent terminals in rat locus ceruleus, in contrast to mitochondrial copper in cerebellum.
J Histochem Cytochem
42:1585-1591.
-
Snow AD,
Mar H,
Nochlin D,
Kimata K,
Kato M,
Suzuki S,
Hassell J,
Wight TN
(1988)
The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease.
Am J Pathol
133:456-463.
-
Suh SW,
Jensen KB,
Jensen MS,
Silva DS,
Kesslak P,
Danscher G,
Frederickson CJ
(1998)
Histologic evidence of a zinc role in Alzheimer's disease.
Soc Neurosci Abstr
24:1217.
-
Vyas SB,
Duffy LK
(1995)
Stabilization of secondary structure of Alzheimer beta-protein by aluminum (III) ions and D-Asp substitutions.
Biochem Biophys Res Commun
206:718-723.
-
Whitfield DM,
Sarkar B
(1992)
Heavy metal binding to heparin disaccharides. II. First evidence for zinc chelation.
Biopolymers
32:597-619.
Copyright © 1999 Society for Neuroscience 0270-6474/99/$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
P. Thomas and M. Fenech
A review of genome mutation and Alzheimer's disease
Mutagenesis,
January 1, 2007;
22(1):
15 - 33.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Maynard, R. Cappai, I. Volitakis, R. A. Cherny, A. R. White, K. Beyreuther, C. L. Masters, A. I. Bush, and Q.-X. Li
Overexpression of Alzheimer's Disease Amyloid-beta Opposes the Age-dependent Elevations of Brain Copper and Iron
J. Biol. Chem.,
November 15, 2002;
277(47):
44670 - 44676.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-Y. Lee, T. B. Cole, R. D. Palmiter, S. W. Suh, and J.-Y. Koh
From the Cover: Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice
PNAS,
May 28, 2002;
99(11):
7705 - 7710.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|